Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06697197 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 413
- Enrollment target
- 20
- Study locations
NCT06697197: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Bristol-Myers Squibb.
NCT06697197 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 413 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (111% higher). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06697197, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 413 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG BMS-986482
- DRUG Nivolumab and rHuPH20
- DRUG Nivolumab/relatlimab/rHuPH20
Study Locations (20)
California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center - Irvine
- The Angeles Clinic and Research Institute - West Los Angeles Office - Los Angeles
Other
- Erasmus Medisch Centrum - Rotterdam
- Hospital Universitario HM Sanchinarro - Madrid
Colorado
- Local Institution - 0008 - Aurora
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
New York
- Northwell Health/ RJ Zuckerberg Cancer Center - Lake Success
North Carolina
- Levine Cancer Institute - Charlotte
Washington
- Fred Hutchinson Cancer Center - Seattle
Oost-Vlaanderen
- UZ Gent - Ghent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2025-02-17 |
| Est. Completion | 2029-01-05 |
| Phase | Phase 1 |
What NCT06697197 shows while recruiting
NCT06697197 is an interventional study that assigns participants to a tested intervention. The registered 413 participants enrollment target is mid-sized for trials with a published cap, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (111% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT06697197 names 20 study sites across 18 states, led by California, Other, Colorado.
Frequently Asked Questions
What is clinical trial NCT06697197 about?
NCT06697197 is a clinical study titled "A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors". The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
What is the current status of trial NCT06697197?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 413 participants. The study started on 2025-02-17. Estimated completion is 2029-01-05.
What conditions does trial NCT06697197 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06697197?
The interventions under investigation include: Bevacizumab (DRUG), BMS-986482 (DRUG), Nivolumab and rHuPH20 (DRUG), Nivolumab/relatlimab/rHuPH20 (DRUG).
Who is sponsoring clinical trial NCT06697197?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06697197 being conducted?
This trial has 20 study locations across California, Colorado, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06697197's enrollment target sits among peer trials
413 13th of 144 higher than 132 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- NCT04776941 · 414 participants · NA
Expressive Writing for the Management of Stress in Cancer Survivors
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI